MAPT P301SP301S final homepage image

cat no | io1008

ioGlutamatergic Neurons
MAPT P301S/P301S

Human iPSC-derived FTD disease model

A rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).

ioGlutamatergic Neurons MAPT P301S/P301S are opti-ox™ precision reprogrammed glutamatergic neurons containing a genetically engineered homozygous P301S mutation in the MAPT gene encoding the tau protein.

 

Request a quote >

 

Place your order

Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.

per vial

Add to basket

Click here for bulk request

Benchtop benefits

phenotype_0

Disease-related phenotype

High content ICC image analysis shows hyperphosphorylation of tau compared to the wild-type control.

comparison_0

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the impact of mutant tau protein on disease.

quick_0

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Technical data

Disease-related phenotype

Hyperphosphorylation of tau observed in the disease model cells compared to the isogenic control
Hyperphosphorylation of tau in glutamatergic neurons FTD disease model cells carrying MAPT P301S or N279K mutation

ioGlutamatergic Neurons disease model cells carrying MAPT P301S/P301S, MAPT N279K/WT and MAPT N279K/N279K mutations show hyperphosphorylation when compared to the isogenic control ioGlutamatergic Neurons (WT) at day 21. The bar graphs show total Tau, pTau217/total Tau, pTau202/5/total Tau or pTau404/total Tau in cell bodies, analysed by immunocytochemistry. Statistical analyses performed on 5 cellular replicates in the same plate. Bars showing mean, error bars showing standard deviation. Statistics calculated by one way ANOVA and Tukey posthoc analysis. Data courtesy of Charles River Laboratories.

Highly characterised and defined

ioGlutamatergic Neurons MAPT P301S/P301S express neuron-specific markers comparably to the isogenic control

ioGlutamatergic Neurons MAPT P301S/P301S ICC single channel and overlays

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons MAPT P301S/P301S compared to the isogenic control. 100X magnification.

ioGlutamatergic Neurons MAPT P301S/P301S form structural neuronal networks by day 11

ioGlutamatergic Neurons MAPT P301S/P301S Brightfield images

ioGlutamatergic Neurons MAPT P301S/P301S mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thaw; 100X magnification.

ioGlutamatergic Neurons MAPT P301S/P301S demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming

ioGlutamatergic Neurons MAPT P301S/P301S rt-qPCR of key markers

Gene expression analysis demonstrates that at day 11, ioGlutamatergic Neurons MAPT P301S/P301S (MAPT P301S/P301S) and the wild type isogenic control (WT) lack the expression of pluripotency makers (NANOG and OCT4) whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR. Data is shown relative to the parental hiPSC control (iPSC Control), normalised to HMBS. Data represents day 11 post-revival samples; n=2 biological replicates.

Disease-related MAPT is expressed in ioGlutamatergic Neurons MAPT P301S/P301S following reprogramming

ioGlutamatergic Neurons MAPT P301S/P301S rt-qPCR of MAPT

RT-qPCR analysis demonstrates similar expression level of the MAPT gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons MAPT P301S/P301S (MAPT P301S/P301S) at day 11 post-revival (n=2 replicates). cDNA samples of the parental iPSC line (iPSC Control) were included as a reference.

Cells arrive ready to plate

ioGlutamatergic Neurons MAPT P301S/P301S arrive ready to plate

ioGlutamatergic Neurons MAPT P301S/P301S are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Industry leading seeding density

Do more with every vial
ioGlut-WT-well_plate-2

ioGlutamatergic Neurons MAPT P301S/P301S cells are compatible with plates ranging from 6 to 384 wells.
The recommended seeding density is 30,000 cells/cm2, compared to up to 500,000 cells/cm2 for other similar products on the market.
This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality, resulting in more experimental conditions, more repeats, and more confidence in the data.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. One Large vial can plate a minimum of 3.6 x 24-well plates, 5.4 x 96-well plates, or 7.75 x 384-well plates.

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 10⁶ viable cells
Large: >5 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm2

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Homozygous P301S missense mutation in the MAPT gene

Applications

FTD research
Drug discovery and development
Disease modelling
High content imaging
Western blotting
Electrophysiological assays (MEA)
Co-culture studies

Product use

ioCells are for research use only

Product resources

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease Poster
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Smith et al. 
bit.bio
2024
Downlaod
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™ Case study
Generating publishable neuroscience research in 12 weeks with ioGlutamatergic Neurons™

Professor Deepak Srivastava

Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders

King’s College London 

Download
Running Large-Scale CRISPR Screens in Human Neurons Webinar
Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency Talk
Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency

Innovation showcase talk at ISSCR

Marius Wernig MD, PhD | Stanford 

Mark Kotter, MD, PhD | bit.bio

Watch now
Modelling neurodegeneration: Human isogenic system to study FTD & ALS Poster
Modelling neurodegeneration: Human isogenic system to study FTD & ALS

Oosterveen, et al

bit.bio & Charles River Laboratories

2023

Download
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now

Addressing current challenges of in vitro cell models 

Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.

bit-bio_Addressing the challenges of cell models_Blog_Image1200x755

Related products

ioGlutamatergic Neurons MAPT P301S/WT™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT P301S/WT™ cat no. io1015
Order now
ioGlutamatergic Neurons MAPT N279K/WT™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/WT™ cat no. io1009
Order now
ioGlutamatergic Neurons MAPT N279K/N279K™ ioDisease Model Cells
ioGlutamatergic Neurons MAPT N279K/N279K™ cat no. io1014
Order now
ioGlutamatergic Neurons™ ioWild Type Cells
ioGlutamatergic Neurons™ cat no. io1001
Order now
CRISPR-Ready ioGlutamatergic Neurons™ ioCRISPR-Ready Cells
CRISPR-Ready ioGlutamatergic Neurons™ cat no. ioEA1090
Order now
ioGlutamatergic Neurons HTT 50CAG/WT™ ioDisease Model Cells
ioGlutamatergic Neurons HTT 50CAG/WT™ cat no. ioEA1004
Order now
ioGlutamatergic Neurons TDP‑43 M337V/WT™ ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/WT™ cat no. ioEA1006
Order now
ioGlutamatergic Neurons PRKN R275W/WT™ ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/WT™ cat no. io1013
Order now
ioGlutamatergic Neurons GBA null/R159W™ ioDisease Model Cells
ioGlutamatergic Neurons GBA null/R159W™ cat no. io1007
Order now
ioGlutamatergic Neurons TDP‑43 M337V/M337V™ ioDisease Model Cells
ioGlutamatergic Neurons TDP‑43 M337V/M337V™ cat no. ioEA1005
Order now
ioGlutamatergic Neurons PRKN R275W/R275W™ ioDisease Model Cells
ioGlutamatergic Neurons PRKN R275W/R275W™ cat no. io1020
Order now

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide

Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery
Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform that powers our ioCells